16 Bit

About 16 Bit

Rho is an AI-driven software that utilizes routinely captured x-rays to identify patients at risk of osteoporosis, addressing the low screening rates among eligible individuals. By integrating seamlessly into existing clinical workflows, Rho enhances population bone health management and improves care quality.

```xml <problem> Osteoporosis often goes undiagnosed because screening rates among eligible individuals are low. Traditional methods require dedicated appointments and are not always integrated into routine care, leading to missed opportunities for early detection and intervention. </problem> <solution> Rho is an AI-driven software designed to identify patients at risk of osteoporosis using routinely captured X-rays. The software seamlessly integrates into existing clinical workflows, analyzing X-ray images to detect indicators of low bone density. By leveraging AI, Rho enables opportunistic screening, ensuring that more individuals at risk are identified and can receive timely intervention. The system enhances population bone health management by providing a user-centric design that fits into current clinical practices, improving the quality of healthcare through intelligent screening. </solution> <features> - AI-driven analysis of routinely captured X-rays to identify potential osteoporosis risk - Seamless integration into existing clinical workflows for opportunistic screening - User-centric design to minimize disruption to clinical practice - FDA De Novo Marketing Authorization - Health Canada licensing - Protected by U.S. Patent No. US11737704B2 </features> <target_audience> The primary target audience includes healthcare providers, radiologists, and hospitals aiming to improve osteoporosis screening rates and enhance bone health management in their patient populations. </target_audience> ```

What does 16 Bit do?

Rho is an AI-driven software that utilizes routinely captured x-rays to identify patients at risk of osteoporosis, addressing the low screening rates among eligible individuals. By integrating seamlessly into existing clinical workflows, Rho enhances population bone health management and improves care quality.

Where is 16 Bit located?

16 Bit is based in Toronto, Canada.

When was 16 Bit founded?

16 Bit was founded in 2016.

How much funding has 16 Bit raised?

16 Bit has raised 3770000.

Location
Toronto, Canada
Founded
2016
Funding
3770000
Employees
8 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

16 Bit

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Rho is an AI-driven software that utilizes routinely captured x-rays to identify patients at risk of osteoporosis, addressing the low screening rates among eligible individuals. By integrating seamlessly into existing clinical workflows, Rho enhances population bone health management and improves care quality.

16bit.ai1K+
Founded 2016Toronto, Canada

Funding

$

Estimated Funding

$3M+

Team (5+)

No team information available.

Company Description

Problem

Osteoporosis often goes undiagnosed because screening rates among eligible individuals are low. Traditional methods require dedicated appointments and are not always integrated into routine care, leading to missed opportunities for early detection and intervention.

Solution

Rho is an AI-driven software designed to identify patients at risk of osteoporosis using routinely captured X-rays. The software seamlessly integrates into existing clinical workflows, analyzing X-ray images to detect indicators of low bone density. By leveraging AI, Rho enables opportunistic screening, ensuring that more individuals at risk are identified and can receive timely intervention. The system enhances population bone health management by providing a user-centric design that fits into current clinical practices, improving the quality of healthcare through intelligent screening.

Features

AI-driven analysis of routinely captured X-rays to identify potential osteoporosis risk

Seamless integration into existing clinical workflows for opportunistic screening

User-centric design to minimize disruption to clinical practice

FDA De Novo Marketing Authorization

Health Canada licensing

Protected by U.S. Patent No. US11737704B2

Target Audience

The primary target audience includes healthcare providers, radiologists, and hospitals aiming to improve osteoporosis screening rates and enhance bone health management in their patient populations.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.